Advertisement

Related Videos

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Opportunities to Optimize Cancer Policies Panel Discussion

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Advertisement

Advertisement




Aug
02
Today In Oncology
ACS Study Quantifies Financial Burden of Cancer in Older Patients
Transplant Consolidation Improves Survival in Primary CNS Lymphoma
Pirtobrutinib Triplet Improves Progression-Free Survival in Previously Treated CLL
NCI Names New CCR Director
Rectal Cancer AI Identifies Patients Most Likely to Benefit From Irinotecan-Intensified Neoadjuvant Chemoradiotherapy
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo